Swiss National Bank Acquires 9,700 Shares of Glaukos Co. (NYSE:GKOS)

Swiss National Bank grew its holdings in Glaukos Co. (NYSE:GKOS) by 9.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 108,100 shares of the medical instruments supplier’s stock after acquiring an additional 9,700 shares during the quarter. Swiss National Bank’s holdings in Glaukos were worth $16,209,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the company. HighTower Advisors LLC grew its holdings in shares of Glaukos by 2.8% during the fourth quarter. HighTower Advisors LLC now owns 3,298 shares of the medical instruments supplier’s stock worth $495,000 after buying an additional 91 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Glaukos by 36.4% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,939 shares of the medical instruments supplier’s stock worth $2,240,000 after buying an additional 3,983 shares in the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Glaukos by 817.2% during the fourth quarter. PNC Financial Services Group Inc. now owns 34,541 shares of the medical instruments supplier’s stock worth $5,179,000 after buying an additional 30,775 shares in the last quarter. Lisanti Capital Growth LLC grew its holdings in shares of Glaukos by 39.7% during the fourth quarter. Lisanti Capital Growth LLC now owns 29,790 shares of the medical instruments supplier’s stock worth $4,467,000 after buying an additional 8,460 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of Glaukos during the fourth quarter worth about $16,910,000. 99.04% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, insider Tomas Navratil sold 3,416 shares of Glaukos stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $147.14, for a total transaction of $502,630.24. Following the completion of the sale, the insider now directly owns 72,437 shares of the company’s stock, valued at approximately $10,658,380.18. This trade represents a 4.50 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Joseph E. Gilliam sold 3,328 shares of the firm’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $149.85, for a total value of $498,700.80. Following the transaction, the chief operating officer now owns 102,169 shares in the company, valued at approximately $15,310,024.65. This trade represents a 3.15 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 16,744 shares of company stock valued at $2,504,131. Insiders own 6.40% of the company’s stock.

Glaukos Stock Performance

GKOS opened at $100.36 on Wednesday. Glaukos Co. has a 12-month low of $85.23 and a 12-month high of $163.71. The stock has a market cap of $5.68 billion, a price-to-earnings ratio of -34.97 and a beta of 0.99. The business has a 50 day moving average of $138.69 and a 200-day moving average of $137.25. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19.

Glaukos (NYSE:GKOS) last released its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.02). The firm had revenue of $105.50 million for the quarter, compared to analyst estimates of $100.72 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. On average, equities research analysts expect that Glaukos Co. will post -1.08 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on GKOS shares. Needham & Company LLC increased their price objective on Glaukos from $149.00 to $176.00 and gave the stock a “buy” rating in a report on Friday, February 21st. Wells Fargo & Company increased their price target on Glaukos from $153.00 to $160.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. BTIG Research increased their price target on Glaukos from $140.00 to $149.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. Citigroup raised Glaukos from a “neutral” rating to a “buy” rating and increased their price target for the company from $132.00 to $162.00 in a research report on Wednesday, December 11th. Finally, Stifel Nicolaus increased their price target on Glaukos from $153.00 to $175.00 and gave the company a “buy” rating in a research report on Tuesday, December 31st. One analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $163.25.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.